ELVN · Enliven Therapeutics, Inc.

Current Thesis

Enliven is transitioning from a "will the BCR::ABL1 drug work" binary to a "best-in-class, ready-for-Phase-3" re-rate. Updated Phase 1 ENABLE efficacy and safety hits an EHA 2026 oral presentation on June 11 (T-4), 5:45 p.m. CEST / 11:45 a.m. ET in Stockholm, paired with an investor webcast the same day. The 60/120 mg dose cohorts have shown 69% cumulative MMR by 24 weeks (26 evaluable) in previously-treated CML, 47% in the mature 80 mg cohort, and 52% in asciminib-pretreated patients efficacy after the current standard fails with no maximum tolerated dose across 141 enrolled at ~32-week median treatment. $462.6M cash at Dec 31 2025 funds operations into 1H 2029, clearing the dilution overhang straight through the Phase 3 ENABLE-2 pivotal launch slated 2H 2026. Theme bucket: biotech-precision-therapeutics, ACCELERATING. The catch: the EHA abstract already carries the prior numbers, so June 11 trades on follow-up durability rather than a first-look surprise. At ~$36 with a $2.2B cap, this is event-window sizing four sessions before a partially-leaked binary a probe corridor, not a fat-pitch build.

Bull Case

• Competitive MMR versus the gold standard: the 60/120 mg cohorts posted 69% cumulative MMR by 24 weeks (26 evaluable) in previously-treated CML (EHA 2026 abstract) adjacent to asciminib's ASC4FIRST 67.7% MMR at 48 weeks (ASCO 2024-06), but in a harder, pretreated population.
• Efficacy after best-in-class fails: 52% cumulative MMR in asciminib-pretreated patients. That is the differentiated commercial wedge a landing spot for patients who cycle off Scemblix, where almost nothing else works.
• Safety is the real edge: no maximum tolerated dose and no new safety signals across 141 enrolled. Legacy TKIs (ponatinib) and even asciminib carry arterial-occlusive and cardiovascular baggage; a clean tolerability profile is the entire pitch.
• Balance sheet removes the overhang: $462.6M cash at Dec 31 2025, runway into 1H 2029. That funds the pivotal without a forced secondary uncommon for a $2.2B-cap clinical-stage name and a sharp upgrade over older ~$280M figures.
• Registrational step-up: Phase 3 ENABLE-2 slated to initiate 2H 2026 after FDA dose alignment. Graduation from Phase 1 to a pivotal trial is the structural re-rate the name is built around.

Bear Case

• The event is half-leaked: the EHA 2026 abstract carries previously-reported numbers (47%/38% in the 80 mg cohort, 52% asciminib-pretreated). June 11 is "updated" follow-up, which caps upside surprise and loads sell-the-news risk onto a stock that already ran from $14.79 to $48.53 over the past year.
• Cross-trial comparisons flatter the asset: asciminib's 67.7% is 1L at 48 weeks; Enliven's 69% is previously-treated at 24 weeks among only 26 evaluable. Small denominators and different treatment lines make the "beats Scemblix" read fragile until Phase 3 controls for it.
• Modest addressable market: CML incidence runs ~8,500 US cases/yr. Even a tolerability winner caps sub-blockbuster absent 1L share capture and ex-US expansion, pushing the revenue case to 2028+.
• Competitor defense is live: Novartis protects the Scemblix franchise aggressively; next-gen asciminib or ASC4START-type data that narrows the tolerability gap blunts the core differentiation.
• Duration mismatch: ENABLE-2 will not read out for years. Between now and then the tape is event-to-event, and a $2.2B cap on a Phase 1 asset already prices a lot of the best-in-class optimism.

Setup & Price Structure

• Last ~$36.03, market cap ~$2.2B, P/E negative (pre-revenue). 52-week range $14.79–$48.53: the stock more than doubled off the 2025 base, topped near $48.53, and now consolidates ~26% below that high into the EHA print.
• The chart remains a higher-low uptrend off the $14.79 low and is technically intact, but $36 is mid-range, not a fresh breakout, so there is no momentum-confirmation tailwind to lean on at this entry.
• The dominant fact: June 11 is a clinical binary four sessions out. Establishing full size inside a pre-binary window is the exact discipline violation sizing exists to prevent, and an incremental update against a partially-leaked abstract is the asymmetric sell-the-news profile to respect.
• Cleaner risk/reward lives in the post-event structure: a gap-and-hold above the high-$30s/$40 on genuinely deeper molecular response confirms the next leg; a sell-the-news flush into the low-$30s/high-$20s that holds the base offers a re-entry with the binary already removed.

Catalyst Calendar (next 30 days)

• 2026-06-11 (T-4) EHA 2026 Congress oral presentation, Stockholm, 5:45 p.m. CEST / 11:45 a.m. ET: updated efficacy and safety from Phase 1 ENABLE in previously-treated CML. The dominant near-term binary.
• 2026-06-11 Investor webcast / conference call to discuss the EHA data (same day; one source also flags a related call ~June 13, 1:30 p.m.).
• 2026-06-11 → 06-14 EHA Congress runs four days; competing CML/TKI readouts can move the whole precision-heme complex into and out of the print.
• 2H 2026 (est.) Phase 3 ENABLE-2 pivotal initiation pending FDA dose alignment; beyond the 30-day window but the structural catalyst the name trades toward.

What Would Change Our Mind

• A daily close below ~$28 breaks the pre-EHA consolidation base and signals the de-risking narrative is rolling over.
• June 11 data showing molecular responses failing to deepen on longer follow-up (flat MR4/MR4.5), or any new Grade ≥3 arterial-occlusive or cardiovascular signal that erases the tolerability advantage versus asciminib.
• ENABLE-2 Phase 3 slipping past 2H 2026, or FDA non-alignment on the registrational dose.
• Novartis next-gen asciminib / ASC4START data that closes the safety gap and reclaims the differentiation.
• A cash-burn guide step-up that compresses the into-1H-2029 runway and reintroduces secondary-offering risk.

Correlation Notes

• Trades as biotech-precision-therapeutics / catalyst-biotech beta, roughly ~1.5x XBI; sector regime (XBI versus its 200DMA, FDA tone on precision oncology) is the macro overlay.
• Conference-day clustering is the trap: stacking ELVN with other EHA-window precision-heme names (KYMR, RLAY, CRNX and peers) collapses several "independent" reads into one concentrated June-11 bet congress-day correlation runs ~0.8.
• Direct mirror to Novartis (NVS / Scemblix franchise): asciminib tolerability and efficacy data is the competitive axis on which ELVN's differentiation rises or falls.
• ELVN-002 (HER2-selective TKI) is background optionality with no fresh 30-day catalyst; the current narrative is entirely ELVN-001 / CML.